AZD1236 + Placebo
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Dec 1, 2009 → Aug 1, 2010
NCT ID
NCT00812045About AZD1236 + Placebo
AZD1236 + Placebo is a phase 2 stage product being developed by AstraZeneca for Cystic Fibrosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00812045. Target conditions include Cystic Fibrosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00812045 | Phase 2 | Withdrawn |
| NCT00758459 | Phase 2 | Completed |
| NCT00758706 | Phase 2 | Completed |
Competing Products
20 competing products in Cystic Fibrosis